Invasive Ductal Carcinoma Survivor Story

What happened, in summary

LAM64 was diagnosed with breast cancer in November 2019 after imaging of the left breast showed a mass at the 3 o’clock position. Follow-up mammogram and ultrasound at Emory Breast Center confirmed the mass and also showed an enlarged left axillary lymph node. Both were biopsied the same day, and just before Thanksgiving she learned that invasive ductal carcinoma was present in the breast mass and the lymph node. Her treatment began with 5 months of chemotherapy. The response was strong: the breast mass completely resolved, and the lymph node returned to normal size. She then had a left mastectomy. Surgery brought more encouraging news because no residual cancer was found in the breast or in the lymph nodes. A few months later, she received 6 weeks of radiation. One major lesson from her diagnosis involved hormone replacement therapy. She had used bioidentical hormone cream for years, starting around age 45, and stopped after a specialist advised her to do so. Her oncologist agreed because the tumor was estrogen-sensitive. LAM64’s story emphasizes treatment response, faith, gratitude, and the importance of understanding how hormone exposure may matter after an estrogen-sensitive breast cancer diagnosis. It also shows how a strong treatment response can reshape later decisions about hormones and survivorship.